E2F transcription factor (E2F)

E2F transcription factor is a family of DNA-binding proteins critically involved in the regulation of the cell cycle, particularly the G1/S transition, DNA synthesis, and various aspects of cell proliferation, differentiation, and apoptosis[1][2][3][5]. The family comprises at least eight members in mammals, which are classified as transcriptional activators (E2F1, E2F2, E2F3a) or repressors (E2F3b, E2F4–E2F8), depending on their functional domains and regulatory partners such as DP proteins and retinoblastoma (Rb) family proteins[1][2][5]. E2F transcription factors control the transcription of numerous genes required for DNA replication and cell cycle progression; their dysregulation is commonly observed in a variety of cancers, driving pathological cell proliferation and sometimes modulating apoptosis[2][5][7][10]. While there are no drugs directly and selectively targeting E2Fs in clinical use, the pathway can be modulated indirectly via therapies targeting cyclin-dependent kinases or the Rb pathway. E2Fs are important biomarkers for tumor aggressiveness and poor prognosis, especially in lung and breast cancers[5][7]. The safety challenge in targeting the E2F pathway lies in its fundamental role in normal tissue homeostasis and proliferation[2][5].

Other names

E2FsE2F familyE2F transcription factor familyE2 promoter binding factor

Inhibition of E2F activity (often via indirect targeting of CDK/Rb pathway) leads to suppression of cell cycle progression and tumor cell proliferation[2][5]. Activation or modulation of E2F-regulated apoptosis (potentially via agents affecting p53 or other co-factors)[3][10].